Ceftazidime-induced thrombocytopenia

Domingo-Chiva, Esther; Díaz-Rangel, M; Monsalve-Naharro, J.Á.; Cuesta-Montero, Pablo; Catalá-Ripoll, José Vicente; García-Martínez, E.M.

doi:10.1016/j.redare.2017.03.009

Cited by 5 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study designed to distribution of the prevalence of the drug induced thrombocytopenia found that the prevalence is 4.7% in selected cities, these findings were similar to the study. [8][9][10][11] the study witnessed that out of 261 samples 165 (63.21%) were males and 96 (58.18%) were females these finding were similar to study [12][13][14][15][16] and the study also found that the age of drug induced thrombocytopenia is similar in all age groups these findings were similar to the study. 17,18…”

Section: Discussionsupporting

confidence: 85%

Prevalence of drug induced thrombocytopenia in five cities of India: A cross sectional descriptive study

Khajuria,

Khattri,

Singh

et al. 2024

PJMS

View full text Add to dashboard Cite

Thrombocytopenia is the condition in which the platelets counts are less than few lakhs and cause the symptoms of the bleeding. The drugs which are used as therapeutic for the management of the diseases, due to adverse effects causes thrombocytopenia. The present study aims to find the prevalence of the drug induced thrombocytopenia in various cities in India: A cross sectional survey study design used to identify the prevalence rate of the drug induced thrombocytopenia in Lucknow 1050 samples, Panipat 1465 samples, Sonipat 815 samples, Gohana 845 samples, Delhi 1265 cities in India a total 5440 samples from 5 cities in north India were selected from different diagnostic centers.: The present study found that in Lucknow total 1050 samples were collected of them 39 samples, in Panipat total 1465 samples were collected 66 samples, in Sonipat total 815 samples were collected of them 63 samples, in Gohana total 845 samples were collected of them 40 samples and in Delhi total 1265 samples were collected of them 53 samples were drug induced thrombocytopenia respectively. The overall prevalence of drug induced thrombocytopenia is 4.7%. Drug induced thrombocytopenia is result of the adverse effect of various group of drugs used as therapeutic management and the prevalence of the drug induced thrombocytopenia is essential to manage and prevent the complication. The present study identified the prevalence of drug induced thrombocytopenia in selected North India.

show abstract

Section: Discussionsupporting

confidence: 85%

Prevalence of drug induced thrombocytopenia in five cities of India: A cross sectional descriptive study

Khajuria,

Khattri,

Singh

et al. 2024

PJMS

View full text Add to dashboard Cite

show abstract

“…Ceftizoxime sodium, ceftazidime, and cefepime are three cephalosporin antibiotics, of which the first two drugs are third-generation cephalosporins, and the last belongs to the fourth generation. A ceftazidime-induced thrombocytopenia case of an adult patient was reported for the first time in the Spanish pharmacovigilance system ( Domingo-Chiva et al, 2017 ). Similarly, there is limited post-marketing surveillance evidence on thrombocytopenia associated with cefepime and ceftizoxime sodium ( Lim et al, 2011 ).…”

Section: Discussionmentioning

confidence: 99%

Detection of Drug-Induced Thrombocytopenia Signals in Children Using Routine Electronic Medical Records

et al. 2021

View full text Add to dashboard Cite

Background: Drug-induced thrombocytopenia (DITP) is a severe adverse reaction and a significantly under-recognized clinical problem in children. However, for post-marketing pharmacovigilance purposes, detection of DITP signals is crucial. This study aimed to develop a signal detection model for DITP using the pediatric electronic medical records (EMR) data.Methods: This study used the electronic medical records collected at Beijing Children’s Hospital between 2009 and 2020. A two-stage modeling method was developed to detect the signal of DITP. In the first stage, we calculated the crude incidence by mining cases of thrombocytopenia to select the potential suspected drugs. In the second stage, we constructed propensity score–matched retrospective cohorts of specific screened drugs from the first stage and estimated the odds ratio (OR) and 95% confidence interval (CI) using conditional logistic regression models. The novelty of the signal was assessed by current evidence.Results: In the study, from a total of 839 drugs, 21 drugs were initially screened as potentially inducing thrombocytopenia. In total, we identified 18 positive DITP associations. Of these, potential DITP risk of nystatin (OR: 1.75, 95% CI: 1.37–2.22) and latamoxef sodium (OR: 1.61, 95% CI: 1.38–1.88) were two new DITP signals in both children and adults. Six associations between thrombocytopenia and drugs including imipenem (OR: 1.69, 95% CI: 1.16–2.45), teicoplanin (OR: 4.75, 95% CI: 3.33–6.78), fusidic acid (OR: 2.81, 95% CI: 2.06–3.86), ceftizoxime sodium (OR: 1.83, 95% CI: 1.36–2.45), ceftazidime (OR: 2.16, 95% CI: 1.58–2.95), and cefepime (OR: 5.06, 95% CI: 3.77–6.78) were considered as new signals in children.Conclusion: This study developed a two-stage algorithm to detect safety signals of DITP and found eighteen positive signals of DITP, including six new signals in a pediatric population. This method is a promising tool for pharmacovigilance based on EMR data.

show abstract

Clinical Efficacy and Safety Evaluation of Ceftazidime-Avibactam in the Treatment of Klebsiella pneumoniae Infection: A Retrospective Analysis from a Hospital in China

Xu,

Luo,

Huang

et al. 2023

IDR

View full text Add to dashboard Cite

Background: Ceftazidime-avibactam (CAZ-AVI) is a new cephalosporin/β-lactamase inhibitor combination that received clinical approval in China in 2019. This study aims to investigate the efficacy and safety of CAZ-AVI in the treatment of Klebsiella pneumoniae (KP) infection in a hospital, and differences in efficacy among various infection sites and between monotherapy and combination therapy, providing valuable insights for its further application. Methods: Patients who used CAZ-AVI between January 2019 and April 2023 were identified through the hospital information system. Demographic information, details of the infection site, KP strain's drug sensitivity report, treatment duration, combination therapies, adverse drug reactions (ADR), and 28-day survival were recorded. Clinical and microbiological efficacies were analyzed using SPSS 23.0 software to compare different infection sites and combination therapies. Results:The overall effective clinical response (CR) rate of CAZ-AVI against KP infection was 62.13%, with a favorable microbial response (MR) rate was 65.68% and a 28-day survival rate was 63.91%. No significant difference occurred in effective CR and 28-day survival rate among different infection sites (P = 0.709 and 0.862, respectively). The favorable MR rate for abdominal infections was slightly lower than that for other sites of infection (P = 0.021). No significant differences in effective CR, favorable MR, and 28-day survival between monotherapy and combination therapy were present (P values were 0.649, 0.123, and 0.280, respectively). The incidence of ADR was 1.78%, including increased creatinine, elevated transaminase, hematuria, and thrombocytopenia. Conclusion: CAZ-AVI demonstrates good clinical efficacy and safety in the treatment of KP infections. The clinical efficacy of CAZ-AVI was similar across different infection sites, and combination therapy did not show an advantage over monotherapy. Further studies are warranted. It should be noted that CAZ-AVI may induce thrombocytopenia and hematuria.

show abstract

Ceftazidime-induced thrombocytopenia

Cited by 5 publications

References 7 publications

Prevalence of drug induced thrombocytopenia in five cities of India: A cross sectional descriptive study

Prevalence of drug induced thrombocytopenia in five cities of India: A cross sectional descriptive study

Detection of Drug-Induced Thrombocytopenia Signals in Children Using Routine Electronic Medical Records

Clinical Efficacy and Safety Evaluation of Ceftazidime-Avibactam in the Treatment of Klebsiella pneumoniae Infection: A Retrospective Analysis from a Hospital in China

Contact Info

Product

Resources

About